Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The azacitidine plus romidepsin clinical trial in lymphoid malignancies

Owen O'Connor • 4 Dec 2015
ASH 2015
B-Cell Lymphoma T-Cell Lymphoma Azacitidine Romidepsin

Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about the Phase I trial (NCT01998035) looking into combining oral 5-azacitidine and romidepsin in patients with B-cell and T-cell lymphoma.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

More from Owen O'Connor

Immunoepigenetic platforms for PTCL treatment
6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
PTCL arising as a PTLD: the efficacy of pralatrexate
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
The role of epigenetic modulators in the pathogenesis of lymphomas
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals